How to Buy Iteos Therapeutics Stock
Iteos Therapeutics Inc
Iteos Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients.
Iteos Therapeutics stock last closed at $10.15, up 0% from the previous day, and has decreased 39.8% in one year. It has overperformed other stocks in the Biotechnology industry by 0.14 percentage points. Iteos Therapeutics stock is currently +111.46% from its 52-week low of $4.80, and -42.43% from its 52-week high of $17.63.
There are currently 44.21M shares of ITOS outstanding. The market cap of ITOS is $448.68M. In the last 24 hours, 0 ITOS shares were traded.
How to Buy Iteos Therapeutics Stock
Wondering how to invest in Iteos Therapeutics stock? Here's how.
- Choose where to buy Iteos Therapeutics stock: You need to decide on a stock brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you figure out where to buy Iteos Therapeutics stock.
- Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit money your brokerage account: Select your payment method and add your information.
- Evaluate Iteos Therapeutics stock: The Iteos Therapeutics ticker symbol is ITOS. Is Iteos Therapeutics stock a good investment? Should you buy shares of ITOS? How do ITOS's underlying business fundamentals look? Do top analysts think Iteos Therapeutics is a good buy? Why has ITOS's stock price moved recently? (Hint: Our stock market research tools can help you evaluate if ITOS is a good stock to buy).
- Place your ITOS trade: Decide if you will purchase ITOS shares at the current market price or use a limit order to purchase ITOS stock at a given price.
- Get key alerts regarding your ITOS position: Create a watchlist to watch your new investment in Iteos Therapeutics stock.
Step 1: Choose where to buy Iteos Therapeutics stock
You will need a brokerage account in order to access the NASDAQ market and buy ITOS stock.
Our preferred brokerage: eToro
Based on our research, eToro is the best stock brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global markets: From Technology to Real Estate, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro has a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've chosen the right brokerage, you'll need to fill out some personal information so you are able to invest in ITOS today.
How to Start a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to open your new brokerage account.
- Submit your data by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit money your brokerage account
Now that you have created your account on the best stock market app for beginners, you need to deposit funds:
Watch the walkthrough below to see the process of depositing money into your new brokerage account.
Step 4: Evaluate Iteos Therapeutics stock
Once you have figured out the best place to buy Iteos Therapeutics stock, it's important to evaluate their stock prior to buying, so you actually understand the risk and opportunity.
Overview of key ITOS info
Fundamentals of ITOS
WallStreetZen was designed to help average investors do better fundamental analysis in less time.
You can see all of the due diligence checks on ITOS's stock page.
How is ITOS stock valued?
Investors use many financial metrics, analyses, models, and charts to gauge ITOS's true value.
Using relative valuations ratios:
- ITOS may be undervalued based on its P/B ratio of 0.91x, relative to Biotechnology industry P/B ratio of 4.56x
You can access more valuation analysis on ITOS's stock here.
ITOS Financials at a glance
Passed Health Checks:
- ITOS has cash burn of 108694000. It has enough cash and short-term investments to cover this for at least one year.
- Total ITOS debt is lower than 5 years ago, relative to shareholder equity.
- ITOS has a low debt to equity ratio of 0.26.
- ITOS has $515.75M in cash and short term investments. This is enough to cover its annual cash burn of $108.69M.
- There are more short-term assets than long-term liabilities on the ITOS balance sheet.
- There are more short-term assets than short-term liabilities on the ITOS balance sheet.
Is Iteos Therapeutics stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 6 Wall Street analysts who give forecasts on ITOS, the consensus analyst rating on Iteos Therapeutics is a Buy
Please note that analyst forecasts are not stock recommendations, nor are they financial advice.
Latest ITOS Analyst Ratings
Swayampakula Ramakanth, a top 7% analyst from HC Wainwright & Co. reiterates ITOS with a buy rating and maintains their ITOS price target from $46.00 to $46.00, on Mar 6, 2025.
You can dive deeper into what analysts are projecting on the Iteos Therapeutics stock forecast page.
ITOS Momentum
ITOS Performance Numbers
Last year, ITOS revenue was $0.00. During the past three year, ITOS's revenue has grown by -100% per year. This was slower than the Biotechnology industry average of 67.2%.
Dive into ITOS's earnings and revenue performance here.
What are ITOS insiders up to?
Over the past year, executives and large shareholders at ITOS have bought more shares than they have sold.
Michel Detheux, Chief Executive Officer of ITOS, was the latest ITOS insider to buy. They bought $36,120.00 worth of ITOS stock on Jun 10, 2025.
Get more info about who owns ITOS stock here.
Does ITOS stock generate passive income?
No, Iteos Therapeutics doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Place your ITOS trade
There are two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are generally the easiest way to buy. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a particular price limit, place a limit order.
Hit the Open Trade button and eToro will execute your order.
If you require additional help investing in stocks on eToro, watch the how to video below:
Step 6: Get key alerts regarding your ITOS position
Now that you own some shares in ITOS, you'll want to keep up with your investment.
Add ITOS to a watchlist to see the latest developments about your ITOS stock.
ITOS Feed
How to Buy Stock in Iteos Therapeutics
To summarize, here are the 6 steps to buy stock in Iteos Therapeutics:
- Choose where to buy Iteos Therapeutics stock
- Create a brokerage account
- Deposit money your brokerage account
- Evaluate Iteos Therapeutics stock
- Place your ITOS trade
- Get key alerts regarding your ITOS position
If you are looking for a online brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to get notifications regarding your investment in Iteos Therapeutics, click below.
Other Stock Buying Guides You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.